Andrea Sowislok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Sowislok has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Jäger
Chair of Orthopedics and Trauma Surgery, University of Duisburg-Essen, 45147 Essen, Germany
9 shared publications - Eleftherios Papaeleftheriou
Chair of Orthopedics and Trauma Surgery, University of Duisburg-Essen, 45147 Essen, Germany
3 shared publications - Emely Rehage
Chair of Orthopedics and Trauma Surgery, University of Duisburg-Essen, 45147 Essen, Germany
2 shared publications - Farnusch Kaschani
University of Duisburg-Essen
2 shared publications - Markus Kaiser
University of Duisburg-Essen
2 shared publications - Melissa Jansen
Institute of Cognitive Science, University of Osnabrück, 49090 Osnabrück, Germany
2 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1086
Extracellular Vesicles and Their Role in Osteogenesis
Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents for bone regeneration due to their ability to modulate osteogenesis, angiogenesis, and immune responses. This review summarizes the current knowledge on EV biology, including their classification, biogenesis, and molecular cargo, with a particular focus on their role in bone healing. EVs derived from mesenchymal stromal cells and other cell types promote osteoblast differentiation, inhibit osteoclast activity, enhance vascularization, and modulate inflammation through the transfer of bioactive proteins and non-coding RNAs. Recent advances in EV engineering, biomaterial-assisted delivery, and isolation techniques are discussed, together with their translational potential for the treatment of critical bone defects and avascular osteonecrosis. Although preclinical evidence is highly encouraging, clinical evidence remains limited, particularly in orthopedics, and clinical translation is challenged by EV heterogeneity, lack of dose standardization, limited understanding of biodistribution, scalable manufacturing, and regulatory requirements. Overall, EV-based therapies represent a promising future strategy for regenerative orthopedics and bone tissue engineering.
- 19 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1086
Open AccessExtracellular Vesicles and Their Role in Osteogenesis
Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents for bone regeneration due to their ability to modulate osteogenesis, angiogenesis, and immune responses. This review summarizes the current knowledge on EV biology, including their classification, biogenesis, and molecular cargo, with a particular focus on their role in bone healing. EVs derived from mesenchymal stromal cells and other cell types promote osteoblast differentiation, inhibit osteoclast activity, enhance vascularization, and modulate inflammation through the transfer of bioactive proteins and non-coding RNAs. Recent advances in EV engineering, biomaterial-assisted delivery, and isolation techniques are discussed, together with their translational potential for the treatment of critical bone defects and avascular osteonecrosis. Although preclinical evidence is highly encouraging, clinical evidence remains limited, particularly in orthopedics, and clinical translation is challenged by EV heterogeneity, lack of dose standardization, limited understanding of biodistribution, scalable manufacturing, and regulatory requirements. Overall, EV-based therapies represent a promising future strategy for regenerative orthopedics and bone tissue engineering.
- Open Access
- 25 August 2026
- Published by MDPI AG in Preprints.org
Extracellular Vesicles and Their Role in Osteogenesis
Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents for bone regeneration due to their ability to modulate osteogenesis, angiogenesis, and immune responses. This review summarizes current knowledge on EV biology, including their classification, biogenesis, and molecular cargo, with a particular focus on their role in bone healing. EVs derived from mesenchymal stromal cells and other cell sources promote osteoblast differentiation, inhibit osteoclast activity, enhance vascularization, and modulate inflammation through the transfer of bioactive proteins and non-coding RNAs. Recent advances in EV engineering, biomaterial-assisted delivery, and isolation techniques are discussed, together with their translational potential for the treatment of critical bone defects and avascular osteonecrosis. Although preclinical evidence is highly encouraging, clinical translation remains limited by challenges in standardization, scalable manufacturing, and regulatory approval. Overall, EV-based therapies represent a promising future strategy for regenerative orthopedics and bone tissue engineering.
- 25 August 2026
- Published by MDPI AG in Preprints.org
Open AccessExtracellular Vesicles and Their Role in Osteogenesis
Extracellular vesicles (EVs) have emerged as promising cell-free therapeutic agents for bone regeneration due to their ability to modulate osteogenesis, angiogenesis, and immune responses. This review summarizes current knowledge on EV biology, including their classification, biogenesis, and molecular cargo, with a particular focus on their role in bone healing. EVs derived from mesenchymal stromal cells and other cell sources promote osteoblast differentiation, inhibit osteoclast activity, enhance vascularization, and modulate inflammation through the transfer of bioactive proteins and non-coding RNAs. Recent advances in EV engineering, biomaterial-assisted delivery, and isolation techniques are discussed, together with their translational potential for the treatment of critical bone defects and avascular osteonecrosis. Although preclinical evidence is highly encouraging, clinical translation remains limited by challenges in standardization, scalable manufacturing, and regulatory approval. Overall, EV-based therapies represent a promising future strategy for regenerative orthopedics and bone tissue engineering.
- Open Access
- 13 May 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (5) , 245
Intraoperative Bioactivation of Bone Substitutes Using a Surgical Suction Handle: A Prospective Clinical Pilot Study
Critical size bone defects (CSBD) remain a major challenge in orthopedic surgery. Autologous bone grafting is considered the gold standard but is limited by restricted availability and significant donor-site morbidity. Synthetic bone substitutes offer an alternative; however, these materials are avital and lack osteoinductive properties. This study evaluated whether intraoperative bioactivation of bone substitutes using a surgical suction handle can safely enhance their regenerative potential. Fifty patients with CSBD, non-unions, or high-risk defects were enrolled, and calcium phosphate-based ceramics were intraoperatively coated with autologous tissue via a surgical suction handle and implanted into the defects. Clinical outcomes—including pain, range of motion, and wound healing—were scored using a standardized system, with all patients achieving results in the “excellent” range (10–13 points). Radiographic follow-up showed progressive cortical and extracortical bone formation in all patients. Surgeons reported high ease-of-use for the device, and no device-related complications occurred. Although biomaterial resorption was incomplete in some cases (36% with <75% resorption at six months), no patient required revision surgery. Our data indicate that intraoperative bioactivation of bone substitutes using a surgical suction handle is safe, feasible, and promotes local bone regeneration, providing a minimally invasive and practical approach to enhance the performance of synthetic grafts in challenging defects.
- 13 May 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (5) , 245
Open AccessIntraoperative Bioactivation of Bone Substitutes Using a Surgical Suction Handle: A Prospective Clinical Pilot Study
Critical size bone defects (CSBD) remain a major challenge in orthopedic surgery. Autologous bone grafting is considered the gold standard but is limited by restricted availability and significant donor-site morbidity. Synthetic bone substitutes offer an alternative; however, these materials are avital and lack osteoinductive properties. This study evaluated whether intraoperative bioactivation of bone substitutes using a surgical suction handle can safely enhance their regenerative potential. Fifty patients with CSBD, non-unions, or high-risk defects were enrolled, and calcium phosphate-based ceramics were intraoperatively coated with autologous tissue via a surgical suction handle and implanted into the defects. Clinical outcomes—including pain, range of motion, and wound healing—were scored using a standardized system, with all patients achieving results in the “excellent” range (10–13 points). Radiographic follow-up showed progressive cortical and extracortical bone formation in all patients. Surgeons reported high ease-of-use for the device, and no device-related complications occurred. Although biomaterial resorption was incomplete in some cases (36% with <75% resorption at six months), no patient required revision surgery. Our data indicate that intraoperative bioactivation of bone substitutes using a surgical suction handle is safe, feasible, and promotes local bone regeneration, providing a minimally invasive and practical approach to enhance the performance of synthetic grafts in challenging defects.
- Open Access
- 12 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 289
A New Subpopulation of Extracellular Vesicles Harvested from Osteogenically Induced Mesenchymal Stromal Cells of Surgical Site-Released Tissue
Impaired bone healing is a major challenge in orthopedic and trauma surgery, often causing long-term disability and high costs. While autologous bone grafting is the gold standard, it is limited by donor site morbidity, low availability, and surgical risks. As an alternative, surgical site-released tissue (SSRT) collected intraoperatively offers a readily available source of regenerative cells and bioactive factors. This study investigates the potential of SSRT-derived mesenchymal stromal cell (MSC)-like cells and their extracellular vesicles (EVs) to support bone healing in a cell-free approach. SSRT samples from 30 patients undergoing elective hip replacement were collected using a surgical vacuum filter. MSC-like cells were isolated and characterized based on International Society for Cellular Therapy (ISCT) criteria. Interestingly, many SSRT-derived MSC-like cells expressed CD34, a marker typically absent in cultured MSCs but linked to tissue-resident stromal cells, suggesting distinct regenerative properties. These cells also showed slow proliferation rates (P1: 8.7 ± 3.2 days; P2: 8.2 ± 5.4 days). EVs were isolated from osteogenically stimulated (EVsMSC/O+) and unstimulated (EVsMSC/O−) MSCs over three weeks. Antibody profiling revealed distinct cargo compositions, with a notable enrichment of CD13+ EVs in the stimulated group. Further in vivo and functional studies are needed to clarify underlying mechanisms and confirm therapeutic efficacy.
- 12 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 289
Open AccessA New Subpopulation of Extracellular Vesicles Harvested from Osteogenically Induced Mesenchymal Stromal Cells of Surgical Site-Released Tissue
Impaired bone healing is a major challenge in orthopedic and trauma surgery, often causing long-term disability and high costs. While autologous bone grafting is the gold standard, it is limited by donor site morbidity, low availability, and surgical risks. As an alternative, surgical site-released tissue (SSRT) collected intraoperatively offers a readily available source of regenerative cells and bioactive factors. This study investigates the potential of SSRT-derived mesenchymal stromal cell (MSC)-like cells and their extracellular vesicles (EVs) to support bone healing in a cell-free approach. SSRT samples from 30 patients undergoing elective hip replacement were collected using a surgical vacuum filter. MSC-like cells were isolated and characterized based on International Society for Cellular Therapy (ISCT) criteria. Interestingly, many SSRT-derived MSC-like cells expressed CD34, a marker typically absent in cultured MSCs but linked to tissue-resident stromal cells, suggesting distinct regenerative properties. These cells also showed slow proliferation rates (P1: 8.7 ± 3.2 days; P2: 8.2 ± 5.4 days). EVs were isolated from osteogenically stimulated (EVsMSC/O+) and unstimulated (EVsMSC/O−) MSCs over three weeks. Antibody profiling revealed distinct cargo compositions, with a notable enrichment of CD13+ EVs in the stimulated group. Further in vivo and functional studies are needed to clarify underlying mechanisms and confirm therapeutic efficacy.
- Open Access
- 9 September 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (9) , 340
Intraoperative Biologization of β-TCP and PCL-TCP by Autologous Proteins
Protein adsorption on orthopedic biomaterials during the initial intraoperative contact critically influences biological responses and osseointegration. Osteoconductive grafts such as β-tricalcium phosphate (β-TCP) and poly (ε-caprolactone)-β-TCP (PCL-TCP) can be functionally activated by exposure to autologous tissue. However, the composition and relevance of the resulting protein layer still remain unclear. In this study involving 10 patients undergoing primary total hip arthroplasty, β-TCP and PCL-TCP samples were incubated both in the femoral medullary cavity and within a surgical tissue collector harvesting autologous tissue (blood, bone fragments, muscle, and fat). Surface morphology was assessed microscopically, and protein adsorption was characterized via high-resolution LC-MS/MS with subsequent bioinformatics and statistical analysis. Both materials adsorbed over 2000 different autologous proteins. β-TCP showed higher overall protein concentrations, while PCL-TCP demonstrated greater proteomic diversity and incubation method-dependent shifts in protein profiles, influenced by surface roughness and wettability. Samples incubated in the tissue collector exhibited less protein variability and smaller material-specific differences compared to incubation in the femoral cavity, particularly for PCL-TCP. Predominant proteins were linked to immune regulation, stress response, and protein metabolism. These findings emphasize the impact of material properties and incubation environment on protein adsorption, with ex vivo incubation leading to more consistent protein adsorption patterns.
- 9 September 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (9) , 340
Open AccessIntraoperative Biologization of β-TCP and PCL-TCP by Autologous Proteins
Protein adsorption on orthopedic biomaterials during the initial intraoperative contact critically influences biological responses and osseointegration. Osteoconductive grafts such as β-tricalcium phosphate (β-TCP) and poly (ε-caprolactone)-β-TCP (PCL-TCP) can be functionally activated by exposure to autologous tissue. However, the composition and relevance of the resulting protein layer still remain unclear. In this study involving 10 patients undergoing primary total hip arthroplasty, β-TCP and PCL-TCP samples were incubated both in the femoral medullary cavity and within a surgical tissue collector harvesting autologous tissue (blood, bone fragments, muscle, and fat). Surface morphology was assessed microscopically, and protein adsorption was characterized via high-resolution LC-MS/MS with subsequent bioinformatics and statistical analysis. Both materials adsorbed over 2000 different autologous proteins. β-TCP showed higher overall protein concentrations, while PCL-TCP demonstrated greater proteomic diversity and incubation method-dependent shifts in protein profiles, influenced by surface roughness and wettability. Samples incubated in the tissue collector exhibited less protein variability and smaller material-specific differences compared to incubation in the femoral cavity, particularly for PCL-TCP. Predominant proteins were linked to immune regulation, stress response, and protein metabolism. These findings emphasize the impact of material properties and incubation environment on protein adsorption, with ex vivo incubation leading to more consistent protein adsorption patterns.
- Open Access
- 9 April 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (4) , 346
Differences in the Synovial Fluid Proteome of Septic and Aseptic Implant Failure
Implant loosening is a severe complication after total joint replacement. Here, differential diagnosis between septic and aseptic cases is crucial for further surgical treatment, but low-grade periprosthetic joint infections (PJIs) in particular remain a challenge. In this study, we analyzed the synovial fluid proteome of 21 patients undergoing revision surgery for septic (eight cases) or aseptic (thirteen cases) implant failure using LC-MS/MS to identify potential new biomarkers as future diagnostic tools. Staphylococci were found in four cases, Streptococci in two cases, Serratia marcescens and Cutibacterium acnes in one case. Proteomic analysis of the synovial fluid resulted in the identification of 515 different proteins based on at least two peptides. A statistical comparison revealed 37 differentially abundant proteins (p < 0.05), of which 17 proteins (46%) showed a higher abundance in the septic group. The proteins with the highest fold change included the known marker proteins c-reactive protein (7.57-fold) and the calprotectin components protein S100-A8 (4.41-fold) and protein S100-A9 (3.1-fold). However, the protein with the highest fold change was leucine-rich alpha-2-glycoprotein 1 (LRG1) (9.07-fold), a currently discussed new biomarker for inflammatory diseases. Elevated LRG1 levels could facilitate the diagnosis of PJI in the future, but their significance needs to be further investigated.
- 9 April 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (4) , 346
Open AccessDifferences in the Synovial Fluid Proteome of Septic and Aseptic Implant Failure
Implant loosening is a severe complication after total joint replacement. Here, differential diagnosis between septic and aseptic cases is crucial for further surgical treatment, but low-grade periprosthetic joint infections (PJIs) in particular remain a challenge. In this study, we analyzed the synovial fluid proteome of 21 patients undergoing revision surgery for septic (eight cases) or aseptic (thirteen cases) implant failure using LC-MS/MS to identify potential new biomarkers as future diagnostic tools. Staphylococci were found in four cases, Streptococci in two cases, Serratia marcescens and Cutibacterium acnes in one case. Proteomic analysis of the synovial fluid resulted in the identification of 515 different proteins based on at least two peptides. A statistical comparison revealed 37 differentially abundant proteins (p < 0.05), of which 17 proteins (46%) showed a higher abundance in the septic group. The proteins with the highest fold change included the known marker proteins c-reactive protein (7.57-fold) and the calprotectin components protein S100-A8 (4.41-fold) and protein S100-A9 (3.1-fold). However, the protein with the highest fold change was leucine-rich alpha-2-glycoprotein 1 (LRG1) (9.07-fold), a currently discussed new biomarker for inflammatory diseases. Elevated LRG1 levels could facilitate the diagnosis of PJI in the future, but their significance needs to be further investigated.
- Open Access
- 1 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15877
Surgical Site-Released Tissue Is Potent to Generate Bone onto TCP and PCL-TCP Scaffolds In Vitro
There is evidence that surgical site tissue (SSRT) released during orthopedic surgery has a strong mesenchymal regenerative potential. Some data also suggest that this tissue may activate synthetic or natural bone substitute materials and can thus upgrade its osteopromoting properties. In this comparative in vitro study, we investigate the composition of SSRT during total hip replacement (n = 20) harvested using a surgical suction handle. In addition, the osteopromoting effect of the cells isolated from SSRT is elucidated when incubated with porous beta-tricalcium phosphate (β-TCP) or 80% medical-grade poly-ε-caprolactone (PCL)/20% TCP composite material. We identified multiple growth factors and cytokines with significantly higher levels of PDGF and VEGF in SSRT compared to peripheral blood. The overall number of MSC was 0.09 ± 0.12‰ per gram of SSRT. A three-lineage specific differentiation was possible in all cases. PCL-TCP cultures showed a higher cell density and cell viability compared to TCP after 6 weeks in vitro. Moreover, PCL-TCP cultures showed a higher osteocalcin expression but no significant differences in osteopontin and collagen I synthesis. We could demonstrate the high regenerative potential from SSRT harvested under vacuum in a PMMA filter device. The in vitro data suggest advantages in cytocompatibility for the PCL-TCP composite compared to TCP alone.
- 1 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15877
Open AccessSurgical Site-Released Tissue Is Potent to Generate Bone onto TCP and PCL-TCP Scaffolds In Vitro
There is evidence that surgical site tissue (SSRT) released during orthopedic surgery has a strong mesenchymal regenerative potential. Some data also suggest that this tissue may activate synthetic or natural bone substitute materials and can thus upgrade its osteopromoting properties. In this comparative in vitro study, we investigate the composition of SSRT during total hip replacement (n = 20) harvested using a surgical suction handle. In addition, the osteopromoting effect of the cells isolated from SSRT is elucidated when incubated with porous beta-tricalcium phosphate (β-TCP) or 80% medical-grade poly-ε-caprolactone (PCL)/20% TCP composite material. We identified multiple growth factors and cytokines with significantly higher levels of PDGF and VEGF in SSRT compared to peripheral blood. The overall number of MSC was 0.09 ± 0.12‰ per gram of SSRT. A three-lineage specific differentiation was possible in all cases. PCL-TCP cultures showed a higher cell density and cell viability compared to TCP after 6 weeks in vitro. Moreover, PCL-TCP cultures showed a higher osteocalcin expression but no significant differences in osteopontin and collagen I synthesis. We could demonstrate the high regenerative potential from SSRT harvested under vacuum in a PMMA filter device. The in vitro data suggest advantages in cytocompatibility for the PCL-TCP composite compared to TCP alone.
- Open Access
- 15 April 2022
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 13 (2) , 44
The Implant Proteome—The Right Surgical Glue to Fix Titanium Implants In Situ
Titanium implants are frequently applied to the bone in orthopedic and trauma surgery. Although these biomaterials are characterized by excellent implant survivorship and clinical outcomes, there are almost no data available on the initial protein layer binding to the implant surface in situ. This study aims to investigate the composition of the initial protein layer on endoprosthetic surfaces as a key initiating step in osseointegration. In patients qualified for total hip arthroplasty, the implants are inserted into the femoral canal, fixed and subsequently explanted after 2 and 5 min. The proteins adsorbed to the surface (the implant proteome) are analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). A statistical analysis of the proteins’ alteration with longer incubation times reveals a slight change in their abundance according to the Vroman effect. The pathways involved in the extracellular matrix organization of bone, sterile inflammation and the beginning of an immunogenic response governed by neutrophils are significantly enriched based on the analysis of the implant proteome. Those are generally not changed with longer incubation times. In summary, proteins relevant for osseointegration are already adsorbed within 2 min in situ. A deeper understanding of the in situ protein–implant interactions in patients may contribute to optimizing implant surfaces in orthopedic and trauma surgery.
- 15 April 2022
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 13 (2) , 44
Open AccessThe Implant Proteome—The Right Surgical Glue to Fix Titanium Implants In Situ
Titanium implants are frequently applied to the bone in orthopedic and trauma surgery. Although these biomaterials are characterized by excellent implant survivorship and clinical outcomes, there are almost no data available on the initial protein layer binding to the implant surface in situ. This study aims to investigate the composition of the initial protein layer on endoprosthetic surfaces as a key initiating step in osseointegration. In patients qualified for total hip arthroplasty, the implants are inserted into the femoral canal, fixed and subsequently explanted after 2 and 5 min. The proteins adsorbed to the surface (the implant proteome) are analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). A statistical analysis of the proteins’ alteration with longer incubation times reveals a slight change in their abundance according to the Vroman effect. The pathways involved in the extracellular matrix organization of bone, sterile inflammation and the beginning of an immunogenic response governed by neutrophils are significantly enriched based on the analysis of the implant proteome. Those are generally not changed with longer incubation times. In summary, proteins relevant for osseointegration are already adsorbed within 2 min in situ. A deeper understanding of the in situ protein–implant interactions in patients may contribute to optimizing implant surfaces in orthopedic and trauma surgery.
- Open Access
- 23 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4412
Functionalization of Synthetic Bone Substitutes
Bone substitutes have been applied to treat osseous defects for a long time. To prevent implant related infection (IRI) and enhance bone healing functionalized biomaterials, antibiotics and osteoinductive substances have been introduced. This study gives an overview of the current available surface-coated bone substitutes and provides an outlook for future perspectives.
- 23 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4412
Open AccessFunctionalization of Synthetic Bone Substitutes
Bone substitutes have been applied to treat osseous defects for a long time. To prevent implant related infection (IRI) and enhance bone healing functionalized biomaterials, antibiotics and osteoinductive substances have been introduced. This study gives an overview of the current available surface-coated bone substitutes and provides an outlook for future perspectives.